Similarities and Differences in the Expression of Drug-Metabolizing Enzymes between Human Hepatic Cell Lines and Primary Human Hepatocytes
In addition to primary human hepatocytes, hepatoma cell lines, and transfected nonhepatoma, hepatic cell lines have been used for pharmacological and toxicological studies. However, a systematic evaluation and a general report of the gene expression spectra of drug-metabolizing enzymes and transport...
Saved in:
Published in | Drug metabolism and disposition Vol. 39; no. 3; pp. 528 - 538 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Bethesda, MD
Elsevier Inc
01.03.2011
American Society for Pharmacology and Experimental Therapeutics The American Society for Pharmacology and Experimental Therapeutics |
Subjects | |
Online Access | Get full text |
ISSN | 0090-9556 1521-009X 1521-009X |
DOI | 10.1124/dmd.110.035873 |
Cover
Abstract | In addition to primary human hepatocytes, hepatoma cell lines, and transfected nonhepatoma, hepatic cell lines have been used for pharmacological and toxicological studies. However, a systematic evaluation and a general report of the gene expression spectra of drug-metabolizing enzymes and transporters (DMETs) in these in vitro systems are not currently available. To fill this information gap and to provide references for future studies, we systematically characterized the basal gene expression profiles of 251 drug-metabolizing enzymes in untreated primary human hepatocytes from six donors, four commonly used hepatoma cell lines (HepG2, Huh7, SK-Hep-1, and Hep3B), and one transfected human liver epithelial cell line. A large variation in DMET expression spectra was observed between hepatic cell lines and primary hepatocytes, with the complete absence or much lower abundance of certain DMETs in hepatic cell lines. Furthermore, the basal DMET expression spectra of five hepatic cell lines are summarized, providing references for researchers to choose carefully appropriate in vitro models for their studies of drug metabolism and toxicity, especially for studies with drugs in which toxicities are mediated through the formation of reactive metabolites. |
---|---|
AbstractList | In addition to primary human hepatocytes, hepatoma cell lines, and transfected nonhepatoma, hepatic cell lines have been used for pharmacological and toxicological studies. However, a systematic evaluation and a general report of the gene expression spectra of drug-metabolizing enzymes and transporters (DMETs) in these in vitro systems are not currently available. To fill this information gap and to provide references for future studies, we systematically characterized the basal gene expression profiles of 251 drug-metabolizing enzymes in untreated primary human hepatocytes from six donors, four commonly used hepatoma cell lines (HepG2, Huh7, SK-Hep-1, and Hep3B), and one transfected human liver epithelial cell line. A large variation in DMET expression spectra was observed between hepatic cell lines and primary hepatocytes, with the complete absence or much lower abundance of certain DMETs in hepatic cell lines. Furthermore, the basal DMET expression spectra of five hepatic cell lines are summarized, providing references for researchers to choose carefully appropriate in vitro models for their studies of drug metabolism and toxicity, especially for studies with drugs in which toxicities are mediated through the formation of reactive metabolites. In addition to primary human hepatocytes, hepatoma cell lines, and transfected nonhepatoma, hepatic cell lines have been used for pharmacological and toxicological studies. However, a systematic evaluation and a general report of the gene expression spectra of drug-metabolizing enzymes and transporters (DMETs) in these in vitro systems are not currently available. To fill this information gap and to provide references for future studies, we systematically characterized the basal gene expression profiles of 251 drug-metabolizing enzymes in untreated primary human hepatocytes from six donors, four commonly used hepatoma cell lines (HepG2, Huh7, SK-Hep-1, and Hep3B), and one transfected human liver epithelial cell line. A large variation in DMET expression spectra was observed between hepatic cell lines and primary hepatocytes, with the complete absence or much lower abundance of certain DMETs in hepatic cell lines. Furthermore, the basal DMET expression spectra of five hepatic cell lines are summarized, providing references for researchers to choose carefully appropriate in vitro models for their studies of drug metabolism and toxicity, especially for studies with drugs in which toxicities are mediated through the formation of reactive metabolites.In addition to primary human hepatocytes, hepatoma cell lines, and transfected nonhepatoma, hepatic cell lines have been used for pharmacological and toxicological studies. However, a systematic evaluation and a general report of the gene expression spectra of drug-metabolizing enzymes and transporters (DMETs) in these in vitro systems are not currently available. To fill this information gap and to provide references for future studies, we systematically characterized the basal gene expression profiles of 251 drug-metabolizing enzymes in untreated primary human hepatocytes from six donors, four commonly used hepatoma cell lines (HepG2, Huh7, SK-Hep-1, and Hep3B), and one transfected human liver epithelial cell line. A large variation in DMET expression spectra was observed between hepatic cell lines and primary hepatocytes, with the complete absence or much lower abundance of certain DMETs in hepatic cell lines. Furthermore, the basal DMET expression spectra of five hepatic cell lines are summarized, providing references for researchers to choose carefully appropriate in vitro models for their studies of drug metabolism and toxicity, especially for studies with drugs in which toxicities are mediated through the formation of reactive metabolites. |
Author | Liu, Jie Fang, Jia-Long Dial, Stacey Deng, Helen Guo, Lei Green, Bridgett Ning, Baitang Shi, Leming Kaput, Jim Branham, William |
Author_xml | – sequence: 1 givenname: Lei surname: Guo fullname: Guo, Lei – sequence: 2 givenname: Stacey surname: Dial fullname: Dial, Stacey – sequence: 3 givenname: Leming surname: Shi fullname: Shi, Leming – sequence: 4 givenname: William surname: Branham fullname: Branham, William – sequence: 5 givenname: Jie surname: Liu fullname: Liu, Jie – sequence: 6 givenname: Jia-Long surname: Fang fullname: Fang, Jia-Long – sequence: 7 givenname: Bridgett surname: Green fullname: Green, Bridgett – sequence: 8 givenname: Helen surname: Deng fullname: Deng, Helen – sequence: 9 givenname: Jim surname: Kaput fullname: Kaput, Jim – sequence: 10 givenname: Baitang surname: Ning fullname: Ning, Baitang email: baitang.ning@fda.hhs.gov |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=23928834$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/21149542$$D View this record in MEDLINE/PubMed |
BookMark | eNp1UsFuEzEQXaEimhauHNFeEKcN9tre2BcklAaKFAQSIHGzHO84HbRrB9sppJ_AV-MoKRSkXjxj-b0388ZzVp344KGqnlIypbTlL_uxLwmZEibkjD2oJlS0tCFEfT2pJiWQRgnRnVZnKX0jhHLO1KPqtKWUK8HbSfXrE444mIgZIdXG9_UFOgcRvC139HW-gnrxcxMhJQy-Dq6-iNt18x6yWYUBb9Cv64W_2Y0FvoL8A8DXl9vRlBM2JqOt5zAM9RL9Uf9jxNHE3V1QsLsM6XH10JkhwZNjPK--vFl8nl82yw9v381fLxsrGM-NcIIVkzOrTEs4dZR1q44QyfpezZxVshiTYsZm0hT7rVs56iTtFLTWcUUMO69eHXQ329UIvQWfoxn05tCXDgb1vy8er_Q6XGtGOiqELAIvjgIxfN9CynrEZItL4yFsk5aiVZTwThTks7ul_tS4nX8BPD8CTLJmcNF4i-kvjqlWSsYLjh9wNoaUIjhtMZfphn2HOGhK9H4ddFmHkhB9WIdCm_5Hu1W-lyAPBCgfcI0QdbK434UeI9is-4D3UX8DFBzLbw |
CODEN | DMDSAI |
CitedBy_id | crossref_primary_10_1155_2015_821761 crossref_primary_10_1517_17425255_2012_685159 crossref_primary_10_1016_j_phrs_2019_04_016 crossref_primary_10_1016_j_tiv_2021_105156 crossref_primary_10_1016_j_tim_2020_06_005 crossref_primary_10_1080_17460441_2017_1271784 crossref_primary_10_3389_fphar_2022_826395 crossref_primary_10_3390_ijms25063265 crossref_primary_10_1016_j_jhep_2015_11_013 crossref_primary_10_1111_liv_14942 crossref_primary_10_1016_j_antiviral_2023_105756 crossref_primary_10_1016_j_ijpharm_2019_118693 crossref_primary_10_1186_s13287_025_04139_2 crossref_primary_10_1038_s41598_019_47114_7 crossref_primary_10_2174_1871530319666191129120253 crossref_primary_10_1016_j_bbalip_2015_10_008 crossref_primary_10_1080_01480545_2016_1255953 crossref_primary_10_1016_S1875_5364_18_30124_9 crossref_primary_10_1007_s00204_018_2196_x crossref_primary_10_1007_s00204_020_02706_5 crossref_primary_10_1016_j_tox_2016_09_012 crossref_primary_10_1124_dmd_114_062836 crossref_primary_10_1002_cptx_66 crossref_primary_10_1089_aivt_2017_0022 crossref_primary_10_3390_ijms25073610 crossref_primary_10_1016_j_apmt_2024_102374 crossref_primary_10_1038_s41598_020_62286_3 crossref_primary_10_1002_jcp_24148 crossref_primary_10_1007_s00204_014_1265_z crossref_primary_10_1038_ncomms4739 crossref_primary_10_1038_s41598_022_18174_z crossref_primary_10_1080_26896583_2022_2044242 crossref_primary_10_1016_j_fct_2021_112355 crossref_primary_10_1093_toxsci_kfu238 crossref_primary_10_3390_cancers11121873 crossref_primary_10_1016_j_bioorg_2023_106801 crossref_primary_10_1093_toxsci_kft254 crossref_primary_10_1007_s13577_017_0175_9 crossref_primary_10_1124_dmd_117_078238 crossref_primary_10_1038_s41598_024_73827_5 crossref_primary_10_1016_j_rvsc_2017_08_006 crossref_primary_10_1177_2211068214566939 crossref_primary_10_1186_1755_8794_8_S2_S5 crossref_primary_10_1016_j_mrgentox_2017_12_005 crossref_primary_10_3390_mi12040418 crossref_primary_10_1080_26896583_2021_1880242 crossref_primary_10_1007_s00204_014_1215_9 crossref_primary_10_1016_j_biomaterials_2013_02_070 crossref_primary_10_1016_j_talanta_2022_123262 crossref_primary_10_2174_1389201021666200422090952 crossref_primary_10_3390_ijms222313135 crossref_primary_10_1155_2023_4399998 crossref_primary_10_1002_bit_28456 crossref_primary_10_1248_bpb_b17_00913 crossref_primary_10_30895_2312_7821_2023_379 crossref_primary_10_1016_j_apsb_2021_11_013 crossref_primary_10_1016_j_mrgentox_2018_06_020 crossref_primary_10_1038_s12276_022_00921_x crossref_primary_10_1021_acs_est_0c03476 crossref_primary_10_1002_em_21817 crossref_primary_10_3390_ijms23179986 crossref_primary_10_1089_aivt_2015_0024 crossref_primary_10_1186_s40580_020_00228_5 crossref_primary_10_1016_j_tox_2024_153829 crossref_primary_10_1016_j_yexcr_2017_12_023 crossref_primary_10_1039_C5OB00427F crossref_primary_10_1039_C6TX00101G crossref_primary_10_1093_toxres_tfac017 crossref_primary_10_3389_fbioe_2018_00120 crossref_primary_10_1016_j_tiv_2013_07_010 crossref_primary_10_1016_j_taap_2014_07_007 crossref_primary_10_1007_s10616_020_00398_4 crossref_primary_10_1016_j_ejphar_2011_05_084 crossref_primary_10_1016_j_scitotenv_2021_151192 crossref_primary_10_1016_j_taap_2019_114790 crossref_primary_10_1093_mutage_gev058 crossref_primary_10_1016_j_etap_2018_06_010 crossref_primary_10_3390_v13010097 crossref_primary_10_1007_s00204_011_0733_y crossref_primary_10_1007_s13346_022_01170_1 crossref_primary_10_1016_j_biochi_2015_07_003 crossref_primary_10_3390_pharmaceutics15041300 crossref_primary_10_51335_organoid_2022_2_e6 crossref_primary_10_1038_s41598_020_77106_x crossref_primary_10_1093_toxsci_kfw173 crossref_primary_10_3389_fmed_2019_00265 crossref_primary_10_1016_j_fct_2015_08_030 crossref_primary_10_1016_j_jep_2014_06_038 crossref_primary_10_1016_j_ijbiomac_2021_06_174 crossref_primary_10_1016_j_tox_2024_153884 crossref_primary_10_1248_bpbreports_3_1_7 crossref_primary_10_1016_j_abb_2023_109536 crossref_primary_10_1016_j_tox_2016_11_014 crossref_primary_10_1016_j_bcp_2015_03_015 crossref_primary_10_1093_carcin_bgs182 crossref_primary_10_1016_j_dmpk_2018_03_003 crossref_primary_10_1111_1541_4337_12280 crossref_primary_10_1016_j_pt_2022_05_014 crossref_primary_10_1016_j_jinorgbio_2023_112252 crossref_primary_10_1007_s11419_020_00562_7 crossref_primary_10_1016_j_tox_2014_05_007 crossref_primary_10_1016_j_stemcr_2020_04_010 crossref_primary_10_1007_s10565_015_9301_1 crossref_primary_10_1124_dmd_123_001396 crossref_primary_10_1016_j_tiv_2015_04_001 crossref_primary_10_1016_j_fct_2014_06_013 crossref_primary_10_1021_tx400317p crossref_primary_10_1021_acsami_1c14401 crossref_primary_10_3892_mmr_2016_4845 crossref_primary_10_1016_j_biomaterials_2012_03_034 crossref_primary_10_1016_j_yexcr_2015_07_004 crossref_primary_10_1007_s00204_016_1893_6 crossref_primary_10_1016_j_actbio_2016_04_042 crossref_primary_10_1016_j_jep_2013_10_021 crossref_primary_10_1021_acs_jmedchem_4c01341 crossref_primary_10_1038_s41536_022_00252_5 crossref_primary_10_1016_j_biomaterials_2012_08_065 crossref_primary_10_3390_bios12030160 crossref_primary_10_1016_S0022_3549_15_00190_2 crossref_primary_10_1242_bio_042192 crossref_primary_10_1038_s41598_017_09321_y crossref_primary_10_1002_dta_3184 crossref_primary_10_1038_s41467_020_15058_6 crossref_primary_10_1093_toxsci_kfx122 crossref_primary_10_1186_s13568_020_01064_w crossref_primary_10_1021_jacs_3c05704 crossref_primary_10_1038_s41746_024_01024_9 crossref_primary_10_1016_j_tiv_2023_105689 crossref_primary_10_1080_14756366_2021_1886093 crossref_primary_10_1128_AAC_01460_21 crossref_primary_10_1016_j_cbi_2021_109531 crossref_primary_10_3389_fgene_2021_767621 crossref_primary_10_1038_srep41238 crossref_primary_10_1021_acs_jmedchem_6b00382 crossref_primary_10_3389_fbioe_2022_845360 crossref_primary_10_1093_toxsci_kfs100 crossref_primary_10_1002_em_22157 crossref_primary_10_1016_j_isci_2023_106395 crossref_primary_10_1063_5_0206271 crossref_primary_10_1134_S1070363224060136 crossref_primary_10_1002_adma_202307673 crossref_primary_10_1097_MOG_0000000000000726 crossref_primary_10_1016_j_tox_2017_10_002 crossref_primary_10_1016_j_toxlet_2024_10_004 crossref_primary_10_1038_srep08534 crossref_primary_10_1016_j_celrep_2016_12_070 crossref_primary_10_1016_j_toxlet_2017_06_005 crossref_primary_10_1080_10408444_2020_1756219 crossref_primary_10_1016_j_biopha_2016_08_009 crossref_primary_10_1089_ten_teb_2016_0031 crossref_primary_10_1007_s00204_016_1694_y crossref_primary_10_1016_j_yexcr_2017_10_017 crossref_primary_10_3389_fbioe_2023_1189726 crossref_primary_10_1124_dmd_122_000906 crossref_primary_10_1016_j_scr_2020_101732 crossref_primary_10_1016_j_etap_2015_10_010 crossref_primary_10_1371_journal_pone_0173825 crossref_primary_10_1002_em_22173 crossref_primary_10_18632_oncotarget_21821 crossref_primary_10_1021_mp500063y crossref_primary_10_3390_mi8010027 crossref_primary_10_1515_hmbci_2023_0012 crossref_primary_10_1089_ars_2017_7086 crossref_primary_10_1002_btpr_2627 crossref_primary_10_4062_biomolther_2016_153 crossref_primary_10_1039_D5TB00074B crossref_primary_10_1371_journal_pone_0060368 crossref_primary_10_3390_ma14216480 crossref_primary_10_1007_s00204_019_02576_6 crossref_primary_10_1016_j_bej_2022_108757 crossref_primary_10_3390_biomedicines11113059 crossref_primary_10_1093_mutage_ger021 crossref_primary_10_1089_aivt_2018_0020 crossref_primary_10_1016_j_tiv_2018_02_014 crossref_primary_10_1016_j_tiv_2018_02_013 crossref_primary_10_1128_AAC_00932_21 crossref_primary_10_1002_em_22197 crossref_primary_10_1016_j_fct_2017_09_042 crossref_primary_10_4162_nrp_2017_11_2_97 crossref_primary_10_1007_s00204_022_03329_8 crossref_primary_10_1302_2046_3758_103_BJR_2020_0412 crossref_primary_10_1016_j_toxlet_2013_05_641 crossref_primary_10_1016_j_cbi_2015_10_009 crossref_primary_10_1128_AAC_00530_12 crossref_primary_10_1186_s13007_019_0487_8 crossref_primary_10_1038_s41598_022_25777_z crossref_primary_10_1016_j_jhazmat_2024_134589 crossref_primary_10_2147_IJN_S478574 crossref_primary_10_3390_toxins11070377 crossref_primary_10_1124_dmd_111_042465 crossref_primary_10_1080_03602532_2022_2064487 crossref_primary_10_1007_s00204_016_1775_y crossref_primary_10_3390_ijms24098121 crossref_primary_10_3390_nu12051440 crossref_primary_10_1016_j_fct_2018_02_036 crossref_primary_10_1016_j_watres_2024_121562 crossref_primary_10_2133_dmpk_DMPK_12_RG_016 crossref_primary_10_1093_toxsci_kfu154 crossref_primary_10_1016_j_neuro_2015_10_014 crossref_primary_10_1016_j_actbio_2020_08_041 crossref_primary_10_3390_biomedicines12061200 crossref_primary_10_3390_cells11020305 crossref_primary_10_2174_0115701638278844231214115102 crossref_primary_10_1007_s00204_022_03381_4 crossref_primary_10_1080_00498254_2019_1683258 crossref_primary_10_3390_plants11212862 crossref_primary_10_1124_jpet_116_235044 crossref_primary_10_3390_ijms22031217 crossref_primary_10_1007_s11626_020_00451_8 crossref_primary_10_1016_j_biomaterials_2012_04_014 crossref_primary_10_1016_j_biomaterials_2020_120611 crossref_primary_10_1055_a_1934_5404 crossref_primary_10_1194_jlr_D120000726 crossref_primary_10_1517_17425255_2014_967680 crossref_primary_10_3390_nu14132768 crossref_primary_10_1371_journal_pone_0160285 crossref_primary_10_1016_j_bbadis_2018_08_038 crossref_primary_10_3233_JCB_189013 crossref_primary_10_1016_j_bcp_2018_06_026 crossref_primary_10_1016_j_jsps_2021_03_002 crossref_primary_10_1089_jmf_2019_0032 crossref_primary_10_2217_bmm_13_154 crossref_primary_10_1016_j_fct_2025_115382 crossref_primary_10_1016_j_bcp_2020_114173 crossref_primary_10_1007_s11356_018_2046_7 crossref_primary_10_3923_ijp_2019_229_237 crossref_primary_10_1124_dmd_115_067348 crossref_primary_10_1182_blood_2016_10_740241 crossref_primary_10_3390_bioengineering10020270 crossref_primary_10_1124_dmd_119_087676 crossref_primary_10_1093_toxsci_kfv117 crossref_primary_10_2174_1871530323666230411100121 crossref_primary_10_1016_j_tiv_2016_04_016 crossref_primary_10_1134_S1607672919060048 crossref_primary_10_1007_s11626_022_00711_9 crossref_primary_10_3390_ijerph110201855 crossref_primary_10_3389_fmedt_2020_611913 crossref_primary_10_1021_ic5028948 crossref_primary_10_1038_srep35633 crossref_primary_10_1002_2211_5463_12948 crossref_primary_10_1007_s10565_017_9392_y crossref_primary_10_3892_etm_2017_4240 crossref_primary_10_1177_02611929221091269 crossref_primary_10_1016_j_aca_2019_04_013 crossref_primary_10_1186_s40779_022_00409_9 crossref_primary_10_1007_s00204_015_1599_1 crossref_primary_10_1093_mutage_ges030 crossref_primary_10_3390_molecules28073021 crossref_primary_10_1089_ten_tea_2023_0212 crossref_primary_10_1002_smll_202006055 |
Cites_doi | 10.1016/j.hep.2003.09.034 10.1016/j.tig.2008.06.001 10.1016/S0928-0987(01)00135-X 10.1177/0091270007312153 10.1016/j.taap.2007.03.032 10.2174/138920008783331086 10.1016/S0014-5793(98)00746-7 10.1016/j.toxlet.2005.06.003 10.1016/j.bmc.2009.09.008 10.1124/dmd.31.8.1035 10.1093/toxsci/kfq026 10.1093/ajhp/59.21.2061 10.1016/j.taap.2010.01.012 10.1073/pnas.90.11.5123 10.1254/jphs.08122FP 10.1124/dmd.109.031831 10.2174/138920008786485128 10.1006/abbi.2001.2499 10.1016/j.tiv.2007.05.014 10.1124/dmd.105.006759 10.1016/S0076-6879(96)72044-X 10.1289/ehp.97105s4829 10.1080/03602530601093489 10.1016/0014-5793(88)81021-4 10.1159/000047798 10.1016/S0041-008X(03)00128-5 10.1371/journal.pbio.0060107 10.1101/gr.103341.109 10.1096/fasebj.10.2.8641560 10.1093/toxsci/kfn056 10.1080/03602530902843483 10.1016/j.cbi.2006.11.002 10.2174/138920008786049302 10.1080/00498250701534893 10.1016/j.jhazmat.2009.04.090 10.1016/j.tox.2004.02.008 10.2174/1389200033489424 10.1016/j.bbamcr.2003.10.017 |
ContentType | Journal Article |
Copyright | 2011 American Society for Pharmacology and Experimental Therapeutics 2015 INIST-CNRS U.S. Government work not protected by U.S. copyright |
Copyright_xml | – notice: 2011 American Society for Pharmacology and Experimental Therapeutics – notice: 2015 INIST-CNRS – notice: U.S. Government work not protected by U.S. copyright |
DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7X8 5PM |
DOI | 10.1124/dmd.110.035873 |
DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1521-009X |
EndPage | 538 |
ExternalDocumentID | PMC3061558 21149542 23928834 10_1124_dmd_110_035873 S0090955624057210 |
Genre | Research Support, U.S. Gov't, P.H.S Comparative Study Journal Article Research Support, N.I.H., Extramural |
GrantInformation_xml | – fundername: NIDDK NIH HHS grantid: N01-DK-7-0004 – fundername: NLM NIH HHS grantid: HHSN267200700004G – fundername: NLM NIH HHS grantid: HHSN267200700004C – fundername: National Institutes of Health grantid: N01-DK-7-0004/HHSN267200700004C |
GroupedDBID | --- .GJ 0R~ 18M 2WC 4.4 53G 5GY 5RE 5VS AAXUO ABJNI ABSQV ACGFO ACGFS ACIWK ACPRK ADBBV AENEX AERNN AFFNX AFOSN AFRAH AI. ALMA_UNASSIGNED_HOLDINGS BAWUL BTFSW CS3 DIK DU5 E3Z EBS EJD F5P F9R FDB GX1 H13 HZ~ IH2 INIJC KQ8 LSO M41 O9- OK1 P2P R0Z RHI ROL RPT SJN TR2 VH1 W8F WH7 WOQ YCJ YHG ZGI ZXP ~KM AALRI AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7X8 5PM |
ID | FETCH-LOGICAL-c534t-5f531527c9a2041f136b60083dd97fc98954857378a0902fbf1f8169e2cf490a3 |
ISSN | 0090-9556 1521-009X |
IngestDate | Thu Aug 21 13:37:58 EDT 2025 Fri Sep 05 11:50:49 EDT 2025 Mon Jul 21 06:06:50 EDT 2025 Mon Jul 21 09:15:30 EDT 2025 Wed Sep 10 05:40:24 EDT 2025 Thu Apr 24 23:02:29 EDT 2025 Sun Apr 06 06:53:04 EDT 2025 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 3 |
Keywords | CV DMET P450 THLE GAPDH PCR ACTB PCA Human Cell line Hepatocyte Digestive system Enzyme Liver Established cell line Primary Drug-metabolizing enzyme In vitro |
Language | English |
License | CC BY 4.0 |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c534t-5f531527c9a2041f136b60083dd97fc98954857378a0902fbf1f8169e2cf490a3 |
Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 |
OpenAccessLink | https://dmd.aspetjournals.org/content/dmd/39/3/528.full.pdf |
PMID | 21149542 |
PQID | 852910465 |
PQPubID | 23479 |
PageCount | 11 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_3061558 proquest_miscellaneous_852910465 pubmed_primary_21149542 pascalfrancis_primary_23928834 crossref_citationtrail_10_1124_dmd_110_035873 crossref_primary_10_1124_dmd_110_035873 elsevier_sciencedirect_doi_10_1124_dmd_110_035873 |
PublicationCentury | 2000 |
PublicationDate | 2011-03-01 |
PublicationDateYYYYMMDD | 2011-03-01 |
PublicationDate_xml | – month: 03 year: 2011 text: 2011-03-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | Bethesda, MD |
PublicationPlace_xml | – name: Bethesda, MD – name: Netherlands |
PublicationTitle | Drug metabolism and disposition |
PublicationTitleAlternate | Drug Metab Dispos |
PublicationYear | 2011 |
Publisher | Elsevier Inc American Society for Pharmacology and Experimental Therapeutics The American Society for Pharmacology and Experimental Therapeutics |
Publisher_xml | – name: Elsevier Inc – name: American Society for Pharmacology and Experimental Therapeutics – name: The American Society for Pharmacology and Experimental Therapeutics |
References | Ma, Woo, McLeod (bib23) 2002; 59 Fink, Ebbesen, Zachar (bib10) 2001; 11 Costa, Kalinichenko, Holterman, Wang (bib6) 2003; 38 Dykens, Jamieson, Marroquin, Nadanaciva, Xu, Dunn, Smith, Will (bib9) 2008; 103 Olsavsky, Page, Johnson, Zarbl, Strom, Omiecinski (bib25) 2007; 222 Wee, Yeo, Zhang, Tan, Lim, Tay, Go (bib35) 2009; 17 Aninat, Piton, Glaise, Le Charpentier, Langouët, Morel, Guguen-Guillouzo, Guillouzo (bib2) 2006; 34 Gilad, Rifkin, Pritchard (bib11) 2008; 24 Gómez-Lechón, Donato, Castell, Jover (bib12) 2003; 4 LeCluyse (bib22) 2001; 13 Jover, Bort, Gómez-Lechón, Castell (bib20) 1998; 431 Henzel, Thorborg, Hofmann, Zimmer, Leuschner (bib14) 2004; 1644 Walsky, Boldt (bib34) 2008; 9 Wilkening, Stahl, Bader (bib37) 2003; 31 Knasmüller, Mersch-Sundermann, Kevekordes, Darroudi, Huber, Hoelzl, Bichler, Majer (bib21) 2004; 198 Yang, Zhang, Molony, Chudin, Hao, Zhu, Gaedigk, Suver, Zhong, Leeder (bib38) 2010; 20 Rudzok, Schlink, Herbarth, Bauer (bib28) 2010; 244 Soars, McGinnity, Grime, Riley (bib31) 2007; 168 Doostdar, Duthie, Burke, Melvin, Grant (bib8) 1988; 241 Huang, Strong, Zhang, Reynolds, Nallani, Temple, Abraham, Habet, Baweja, Burckart (bib18) 2008; 48 Zhou, Liu, Chowbay (bib40) 2009; 41 Shiizaki, Ohsako, Koyama, Nagata, Yonemoto, Tohyama (bib30) 2005; 160 Hart, Li, Nakamoto, Subileau, Steen, Zhong (bib13) 2010; 38 Jennen, Magkoufopoulou, Ketelslegers, van Herwijnen, Kleinjans, van Delft (bib19) 2010; 115 Schadt, Molony, Chudin, Hao, Yang, Lum, Kasarskis, Zhang, Wang, Suver (bib29) 2008; 6 Cereghini (bib4) 1996; 10 Hewitt, Lechón, Houston, Hallifax, Brown, Maurel, Kenna, Gustavsson, Lohmann, Skonberg (bib15) 2007; 39 Brandon, Raap, Meijerman, Beijnen, Schellens (bib3) 2003; 189 Hewitt, Lecluyse, Ferguson (bib16) 2007; 37 Rodríguez-Antona, Donato, Pareja, Gómez-Lechón, Castell (bib27) 2001; 393 Ando, Saka, Ando, Sawa, Muro, Ueoka, Yokoyama, Saitoh, Shimokata, Hasegawa (bib1) 2000; 60 Hirth, Watkins, Strawderman, Schott, Bruno, Baker (bib17) 2000; 6 Westerink, Schoonen (bib36) 2007; 21 Donato, Lahoz, Castell, Gómez-Lechón (bib7) 2008; 9 Norppa (bib24) 1997; 105 Zhou, Di, Chan, Du, Chow, Xue, Lai, Wang, Li, Tian (bib39) 2008; 9 Chao, Tsou, Chen, Chang, Tsai, Lin, Chen, Wang (bib5) 2009; 170 Strom, Pisarov, Dorko, Thompson, Schuetz, Schuetz (bib32) 1996; 272 Pfeifer, Cole, Smoot, Weston, Groopman, Shields, Vignaud, Juillerat, Lipsky, Trump (bib26) 1993; 90 Suzuki, Oguro, Osada-Oka, Funae, Imaoka (bib33) 2008; 108 Zhou (10.1124/dmd.110.035873_bib39) 2008; 9 Soars (10.1124/dmd.110.035873_bib31) 2007; 168 Westerink (10.1124/dmd.110.035873_bib36) 2007; 21 Hart (10.1124/dmd.110.035873_bib13) 2010; 38 Aninat (10.1124/dmd.110.035873_bib2) 2006; 34 Knasmüller (10.1124/dmd.110.035873_bib21) 2004; 198 Henzel (10.1124/dmd.110.035873_bib14) 2004; 1644 Ma (10.1124/dmd.110.035873_bib23) 2002; 59 Jover (10.1124/dmd.110.035873_bib20) 1998; 431 Doostdar (10.1124/dmd.110.035873_bib8) 1988; 241 Dykens (10.1124/dmd.110.035873_bib9) 2008; 103 Olsavsky (10.1124/dmd.110.035873_bib25) 2007; 222 Fink (10.1124/dmd.110.035873_bib10) 2001; 11 Pfeifer (10.1124/dmd.110.035873_bib26) 1993; 90 Ando (10.1124/dmd.110.035873_bib1) 2000; 60 Brandon (10.1124/dmd.110.035873_bib3) 2003; 189 Hewitt (10.1124/dmd.110.035873_bib15) 2007; 39 Huang (10.1124/dmd.110.035873_bib18) 2008; 48 Yang (10.1124/dmd.110.035873_bib38) 2010; 20 Zhou (10.1124/dmd.110.035873_bib40) 2009; 41 Walsky (10.1124/dmd.110.035873_bib34) 2008; 9 Rodríguez-Antona (10.1124/dmd.110.035873_bib27) 2001; 393 Schadt (10.1124/dmd.110.035873_bib29) 2008; 6 Norppa (10.1124/dmd.110.035873_bib24) 1997; 105 Cereghini (10.1124/dmd.110.035873_bib4) 1996; 10 Costa (10.1124/dmd.110.035873_bib6) 2003; 38 Jennen (10.1124/dmd.110.035873_bib19) 2010; 115 Wilkening (10.1124/dmd.110.035873_bib37) 2003; 31 Suzuki (10.1124/dmd.110.035873_bib33) 2008; 108 Gilad (10.1124/dmd.110.035873_bib11) 2008; 24 LeCluyse (10.1124/dmd.110.035873_bib22) 2001; 13 Strom (10.1124/dmd.110.035873_bib32) 1996; 272 Wee (10.1124/dmd.110.035873_bib35) 2009; 17 Rudzok (10.1124/dmd.110.035873_bib28) 2010; 244 Hewitt (10.1124/dmd.110.035873_bib16) 2007; 37 Donato (10.1124/dmd.110.035873_bib7) 2008; 9 Shiizaki (10.1124/dmd.110.035873_bib30) 2005; 160 Chao (10.1124/dmd.110.035873_bib5) 2009; 170 Hirth (10.1124/dmd.110.035873_bib17) 2000; 6 Gómez-Lechón (10.1124/dmd.110.035873_bib12) 2003; 4 |
References_xml | – volume: 9 start-page: 1 year: 2008 end-page: 11 ident: bib7 article-title: Cell lines: a tool for in vitro drug metabolism studies publication-title: Curr Drug Metab – volume: 6 start-page: 1255 year: 2000 end-page: 1258 ident: bib17 article-title: The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance publication-title: Clin Cancer Res – volume: 48 start-page: 662 year: 2008 end-page: 670 ident: bib18 article-title: New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process publication-title: J Clin Pharmacol – volume: 31 start-page: 1035 year: 2003 end-page: 1042 ident: bib37 article-title: Comparison of primary human hepatocytes and hepatoma cell line Hepg2 with regard to their biotransformation properties publication-title: Drug Metab Dispos – volume: 393 start-page: 308 year: 2001 end-page: 315 ident: bib27 article-title: Cytochrome P-450 mRNA expression in human liver and its relationship with enzyme activity publication-title: Arch Biochem Biophys – volume: 9 start-page: 928 year: 2008 end-page: 939 ident: bib34 article-title: In vitro cytochrome P450 inhibition and induction publication-title: Curr Drug Metab – volume: 38 start-page: 988 year: 2010 end-page: 994 ident: bib13 article-title: A comparison of whole genome gene expression profiles of HepaRG cells and HepG2 cells to primary human hepatocytes and human liver tissues publication-title: Drug Metab Dispos – volume: 244 start-page: 336 year: 2010 end-page: 343 ident: bib28 article-title: Measuring and modeling of binary mixture effects of pharmaceuticals and nickel on cell viability/cytotoxicity in the human hepatoma derived cell line HepG2 publication-title: Toxicol Appl Pharmacol – volume: 34 start-page: 75 year: 2006 end-page: 83 ident: bib2 article-title: Expression of cytochromes P450, conjugating enzymes and nuclear receptors in human hepatoma HepaRG cells publication-title: Drug Metab Dispos – volume: 21 start-page: 1581 year: 2007 end-page: 1591 ident: bib36 article-title: Cytochrome P450 enzyme levels in HepG2 cells and cryopreserved primary human hepatocytes and their induction in HepG2 cells publication-title: Toxicol In Vitro – volume: 189 start-page: 233 year: 2003 end-page: 246 ident: bib3 article-title: An update on in vitro test methods in human hepatic drug biotransformation research: pros and cons publication-title: Toxicol Appl Pharmacol – volume: 17 start-page: 7562 year: 2009 end-page: 7571 ident: bib35 article-title: Synthesis and evaluation of functionalized isoindigos as antiproliferative agents publication-title: Bioorg Med Chem – volume: 10 start-page: 267 year: 1996 end-page: 282 ident: bib4 article-title: Liver-enriched transcription factors and hepatocyte differentiation publication-title: FASEB J – volume: 222 start-page: 42 year: 2007 end-page: 56 ident: bib25 article-title: Gene expression profiling and differentiation assessment in primary human hepatocyte cultures, established hepatoma cell lines, and human liver tissues publication-title: Toxicol Appl Pharmacol – volume: 41 start-page: 89 year: 2009 end-page: 295 ident: bib40 article-title: Polymorphism of human cytochrome P450 enzymes and its clinical impact publication-title: Drug Metab Rev – volume: 115 start-page: 66 year: 2010 end-page: 79 ident: bib19 article-title: Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification publication-title: Toxicol Sci – volume: 103 start-page: 335 year: 2008 end-page: 345 ident: bib9 article-title: In vitro assessment of mitochondrial dysfunction and cytotoxicity of nefazodone, trazodone, and buspirone publication-title: Toxicol Sci – volume: 38 start-page: 1331 year: 2003 end-page: 1347 ident: bib6 article-title: Transcription factors in liver development, differentiation, and regeneration publication-title: Hepatology – volume: 59 start-page: 2061 year: 2002 end-page: 2069 ident: bib23 article-title: Genetic basis of drug metabolism publication-title: Am J Health Syst Pharm – volume: 20 start-page: 1020 year: 2010 end-page: 1036 ident: bib38 article-title: Systematic genetic and genomic analysis of cytochrome P450 enzyme activities in human liver publication-title: Genome Res – volume: 11 start-page: 105 year: 2001 end-page: 114 ident: bib10 article-title: Quantitative gene expression profiles of human liver-derived cell lines exposed to moderate hypoxia publication-title: Cell Physiol Biochem – volume: 13 start-page: 343 year: 2001 end-page: 368 ident: bib22 article-title: Human hepatocyte culture systems for the in vitro evaluation of cytochrome P450 expression and regulation publication-title: Eur J Pharm Sci – volume: 272 start-page: 388 year: 1996 end-page: 401 ident: bib32 article-title: Use of human hepatocytes to study P450 gene induction publication-title: Methods Enzymol – volume: 60 start-page: 6921 year: 2000 end-page: 6926 ident: bib1 article-title: Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis publication-title: Cancer Res – volume: 170 start-page: 351 year: 2009 end-page: 356 ident: bib5 article-title: The inhibition effect of 2,3,7,8-tetrachlorinated dibenzo-p-dioxin-induced aryl hydrocarbon receptor activation in human hepatoma cells with the treatment of cadmium chloride publication-title: J Hazard Mater – volume: 37 start-page: 1196 year: 2007 end-page: 1224 ident: bib16 article-title: Induction of hepatic cytochrome P450 enzymes: methods, mechanisms, recommendations, and in vitro-in vivo correlations publication-title: Xenobiotica – volume: 6 start-page: e107 year: 2008 ident: bib29 article-title: Mapping the genetic architecture of gene expression in human liver publication-title: PLoS Biol – volume: 9 start-page: 738 year: 2008 end-page: 784 ident: bib39 article-title: Clinical pharmacogenetics and potential application in personalized medicine publication-title: Curr Drug Metab – volume: 160 start-page: 22 year: 2005 end-page: 33 ident: bib30 article-title: Lack of CYP1A1 expression is involved in unresponsiveness of the human hepatoma cell line SK-HEP-1 to dioxin publication-title: Toxicol Lett – volume: 24 start-page: 408 year: 2008 end-page: 415 ident: bib11 article-title: Revealing the architecture of gene regulation: the promise of eQTL studies publication-title: Trends Genet – volume: 198 start-page: 315 year: 2004 end-page: 328 ident: bib21 article-title: Use of human-derived liver cell lines for the detection of environmental and dietary genotoxicants; current state of knowledge publication-title: Toxicology – volume: 4 start-page: 292 year: 2003 end-page: 312 ident: bib12 article-title: Human hepatocytes as a tool for studying toxicity and drug metabolism publication-title: Curr Drug Metab – volume: 431 start-page: 227 year: 1998 end-page: 230 ident: bib20 article-title: Re-expression of C/EBPα induces CYP2B6, CYP2C9 and CYP2D6 genes in HepG2 cells publication-title: FEBS Lett – volume: 108 start-page: 79 year: 2008 end-page: 88 ident: bib33 article-title: Epoxyeicosatrienoic acids and/or their metabolites promote hypoxic response of cells publication-title: J Pharmacol Sci – volume: 1644 start-page: 37 year: 2004 end-page: 45 ident: bib14 article-title: Toxicity of ethanol and acetaldehyde in hepatocytes treated with ursodeoxycholic or tauroursodeoxycholic acid publication-title: Biochim Biophys Acta – volume: 241 start-page: 15 year: 1988 end-page: 18 ident: bib8 article-title: The influence of culture medium composition on drug metabolising enzyme activities of the human liver derived Hep G2 cell line publication-title: FEBS Lett – volume: 90 start-page: 5123 year: 1993 end-page: 5127 ident: bib26 article-title: Simian virus 40 large tumor antigen-immortalized normal human liver epithelial cells express hepatocyte characteristics and metabolize chemical carcinogens publication-title: Proc Natl Acad Sci USA – volume: 105 start-page: 829 year: 1997 end-page: 835 ident: bib24 article-title: Cytogenetic markers of susceptibility: influence of polymorphic carcinogen-metabolizing enzymes publication-title: Environ Health Perspect – volume: 39 start-page: 159 year: 2007 end-page: 234 ident: bib15 article-title: Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies publication-title: Drug Metab Rev – volume: 168 start-page: 2 year: 2007 end-page: 15 ident: bib31 article-title: The pivotal role of hepatocytes in drug discovery publication-title: Chem Biol Interact – volume: 38 start-page: 1331 year: 2003 ident: 10.1124/dmd.110.035873_bib6 article-title: Transcription factors in liver development, differentiation, and regeneration publication-title: Hepatology doi: 10.1016/j.hep.2003.09.034 – volume: 24 start-page: 408 year: 2008 ident: 10.1124/dmd.110.035873_bib11 article-title: Revealing the architecture of gene regulation: the promise of eQTL studies publication-title: Trends Genet doi: 10.1016/j.tig.2008.06.001 – volume: 13 start-page: 343 year: 2001 ident: 10.1124/dmd.110.035873_bib22 article-title: Human hepatocyte culture systems for the in vitro evaluation of cytochrome P450 expression and regulation publication-title: Eur J Pharm Sci doi: 10.1016/S0928-0987(01)00135-X – volume: 48 start-page: 662 year: 2008 ident: 10.1124/dmd.110.035873_bib18 article-title: New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process publication-title: J Clin Pharmacol doi: 10.1177/0091270007312153 – volume: 222 start-page: 42 year: 2007 ident: 10.1124/dmd.110.035873_bib25 article-title: Gene expression profiling and differentiation assessment in primary human hepatocyte cultures, established hepatoma cell lines, and human liver tissues publication-title: Toxicol Appl Pharmacol doi: 10.1016/j.taap.2007.03.032 – volume: 9 start-page: 1 year: 2008 ident: 10.1124/dmd.110.035873_bib7 article-title: Cell lines: a tool for in vitro drug metabolism studies publication-title: Curr Drug Metab doi: 10.2174/138920008783331086 – volume: 431 start-page: 227 year: 1998 ident: 10.1124/dmd.110.035873_bib20 article-title: Re-expression of C/EBPα induces CYP2B6, CYP2C9 and CYP2D6 genes in HepG2 cells publication-title: FEBS Lett doi: 10.1016/S0014-5793(98)00746-7 – volume: 160 start-page: 22 year: 2005 ident: 10.1124/dmd.110.035873_bib30 article-title: Lack of CYP1A1 expression is involved in unresponsiveness of the human hepatoma cell line SK-HEP-1 to dioxin publication-title: Toxicol Lett doi: 10.1016/j.toxlet.2005.06.003 – volume: 17 start-page: 7562 year: 2009 ident: 10.1124/dmd.110.035873_bib35 article-title: Synthesis and evaluation of functionalized isoindigos as antiproliferative agents publication-title: Bioorg Med Chem doi: 10.1016/j.bmc.2009.09.008 – volume: 31 start-page: 1035 year: 2003 ident: 10.1124/dmd.110.035873_bib37 article-title: Comparison of primary human hepatocytes and hepatoma cell line Hepg2 with regard to their biotransformation properties publication-title: Drug Metab Dispos doi: 10.1124/dmd.31.8.1035 – volume: 115 start-page: 66 year: 2010 ident: 10.1124/dmd.110.035873_bib19 article-title: Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification publication-title: Toxicol Sci doi: 10.1093/toxsci/kfq026 – volume: 59 start-page: 2061 year: 2002 ident: 10.1124/dmd.110.035873_bib23 article-title: Genetic basis of drug metabolism publication-title: Am J Health Syst Pharm doi: 10.1093/ajhp/59.21.2061 – volume: 244 start-page: 336 year: 2010 ident: 10.1124/dmd.110.035873_bib28 article-title: Measuring and modeling of binary mixture effects of pharmaceuticals and nickel on cell viability/cytotoxicity in the human hepatoma derived cell line HepG2 publication-title: Toxicol Appl Pharmacol doi: 10.1016/j.taap.2010.01.012 – volume: 90 start-page: 5123 year: 1993 ident: 10.1124/dmd.110.035873_bib26 article-title: Simian virus 40 large tumor antigen-immortalized normal human liver epithelial cells express hepatocyte characteristics and metabolize chemical carcinogens publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.90.11.5123 – volume: 108 start-page: 79 year: 2008 ident: 10.1124/dmd.110.035873_bib33 article-title: Epoxyeicosatrienoic acids and/or their metabolites promote hypoxic response of cells publication-title: J Pharmacol Sci doi: 10.1254/jphs.08122FP – volume: 38 start-page: 988 year: 2010 ident: 10.1124/dmd.110.035873_bib13 article-title: A comparison of whole genome gene expression profiles of HepaRG cells and HepG2 cells to primary human hepatocytes and human liver tissues publication-title: Drug Metab Dispos doi: 10.1124/dmd.109.031831 – volume: 9 start-page: 928 year: 2008 ident: 10.1124/dmd.110.035873_bib34 article-title: In vitro cytochrome P450 inhibition and induction publication-title: Curr Drug Metab doi: 10.2174/138920008786485128 – volume: 393 start-page: 308 year: 2001 ident: 10.1124/dmd.110.035873_bib27 article-title: Cytochrome P-450 mRNA expression in human liver and its relationship with enzyme activity publication-title: Arch Biochem Biophys doi: 10.1006/abbi.2001.2499 – volume: 21 start-page: 1581 year: 2007 ident: 10.1124/dmd.110.035873_bib36 article-title: Cytochrome P450 enzyme levels in HepG2 cells and cryopreserved primary human hepatocytes and their induction in HepG2 cells publication-title: Toxicol In Vitro doi: 10.1016/j.tiv.2007.05.014 – volume: 34 start-page: 75 year: 2006 ident: 10.1124/dmd.110.035873_bib2 article-title: Expression of cytochromes P450, conjugating enzymes and nuclear receptors in human hepatoma HepaRG cells publication-title: Drug Metab Dispos doi: 10.1124/dmd.105.006759 – volume: 272 start-page: 388 year: 1996 ident: 10.1124/dmd.110.035873_bib32 article-title: Use of human hepatocytes to study P450 gene induction publication-title: Methods Enzymol doi: 10.1016/S0076-6879(96)72044-X – volume: 105 start-page: 829 issue: Suppl 4 year: 1997 ident: 10.1124/dmd.110.035873_bib24 article-title: Cytogenetic markers of susceptibility: influence of polymorphic carcinogen-metabolizing enzymes publication-title: Environ Health Perspect doi: 10.1289/ehp.97105s4829 – volume: 39 start-page: 159 year: 2007 ident: 10.1124/dmd.110.035873_bib15 article-title: Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies publication-title: Drug Metab Rev doi: 10.1080/03602530601093489 – volume: 241 start-page: 15 year: 1988 ident: 10.1124/dmd.110.035873_bib8 article-title: The influence of culture medium composition on drug metabolising enzyme activities of the human liver derived Hep G2 cell line publication-title: FEBS Lett doi: 10.1016/0014-5793(88)81021-4 – volume: 11 start-page: 105 year: 2001 ident: 10.1124/dmd.110.035873_bib10 article-title: Quantitative gene expression profiles of human liver-derived cell lines exposed to moderate hypoxia publication-title: Cell Physiol Biochem doi: 10.1159/000047798 – volume: 6 start-page: 1255 year: 2000 ident: 10.1124/dmd.110.035873_bib17 article-title: The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance publication-title: Clin Cancer Res – volume: 189 start-page: 233 year: 2003 ident: 10.1124/dmd.110.035873_bib3 article-title: An update on in vitro test methods in human hepatic drug biotransformation research: pros and cons publication-title: Toxicol Appl Pharmacol doi: 10.1016/S0041-008X(03)00128-5 – volume: 6 start-page: e107 year: 2008 ident: 10.1124/dmd.110.035873_bib29 article-title: Mapping the genetic architecture of gene expression in human liver publication-title: PLoS Biol doi: 10.1371/journal.pbio.0060107 – volume: 20 start-page: 1020 year: 2010 ident: 10.1124/dmd.110.035873_bib38 article-title: Systematic genetic and genomic analysis of cytochrome P450 enzyme activities in human liver publication-title: Genome Res doi: 10.1101/gr.103341.109 – volume: 60 start-page: 6921 year: 2000 ident: 10.1124/dmd.110.035873_bib1 article-title: Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis publication-title: Cancer Res – volume: 10 start-page: 267 year: 1996 ident: 10.1124/dmd.110.035873_bib4 article-title: Liver-enriched transcription factors and hepatocyte differentiation publication-title: FASEB J doi: 10.1096/fasebj.10.2.8641560 – volume: 103 start-page: 335 year: 2008 ident: 10.1124/dmd.110.035873_bib9 article-title: In vitro assessment of mitochondrial dysfunction and cytotoxicity of nefazodone, trazodone, and buspirone publication-title: Toxicol Sci doi: 10.1093/toxsci/kfn056 – volume: 41 start-page: 89 year: 2009 ident: 10.1124/dmd.110.035873_bib40 article-title: Polymorphism of human cytochrome P450 enzymes and its clinical impact publication-title: Drug Metab Rev doi: 10.1080/03602530902843483 – volume: 168 start-page: 2 year: 2007 ident: 10.1124/dmd.110.035873_bib31 article-title: The pivotal role of hepatocytes in drug discovery publication-title: Chem Biol Interact doi: 10.1016/j.cbi.2006.11.002 – volume: 9 start-page: 738 year: 2008 ident: 10.1124/dmd.110.035873_bib39 article-title: Clinical pharmacogenetics and potential application in personalized medicine publication-title: Curr Drug Metab doi: 10.2174/138920008786049302 – volume: 37 start-page: 1196 year: 2007 ident: 10.1124/dmd.110.035873_bib16 article-title: Induction of hepatic cytochrome P450 enzymes: methods, mechanisms, recommendations, and in vitro-in vivo correlations publication-title: Xenobiotica doi: 10.1080/00498250701534893 – volume: 170 start-page: 351 year: 2009 ident: 10.1124/dmd.110.035873_bib5 article-title: The inhibition effect of 2,3,7,8-tetrachlorinated dibenzo-p-dioxin-induced aryl hydrocarbon receptor activation in human hepatoma cells with the treatment of cadmium chloride publication-title: J Hazard Mater doi: 10.1016/j.jhazmat.2009.04.090 – volume: 198 start-page: 315 year: 2004 ident: 10.1124/dmd.110.035873_bib21 article-title: Use of human-derived liver cell lines for the detection of environmental and dietary genotoxicants; current state of knowledge publication-title: Toxicology doi: 10.1016/j.tox.2004.02.008 – volume: 4 start-page: 292 year: 2003 ident: 10.1124/dmd.110.035873_bib12 article-title: Human hepatocytes as a tool for studying toxicity and drug metabolism publication-title: Curr Drug Metab doi: 10.2174/1389200033489424 – volume: 1644 start-page: 37 year: 2004 ident: 10.1124/dmd.110.035873_bib14 article-title: Toxicity of ethanol and acetaldehyde in hepatocytes treated with ursodeoxycholic or tauroursodeoxycholic acid publication-title: Biochim Biophys Acta doi: 10.1016/j.bbamcr.2003.10.017 |
SSID | ssj0014439 |
Score | 2.4966726 |
Snippet | In addition to primary human hepatocytes, hepatoma cell lines, and transfected nonhepatoma, hepatic cell lines have been used for pharmacological and... |
SourceID | pubmedcentral proquest pubmed pascalfrancis crossref elsevier |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 528 |
SubjectTerms | Algorithms Biological and medical sciences Biological Transport Cell Line Cell Line, Tumor Cells, Cultured Drug Evaluation, Preclinical - methods Gene Expression Profiling Gene Expression Regulation, Enzymologic Hepatocytes - enzymology Hepatocytes - metabolism Humans Inactivation, Metabolic Medical sciences Membrane Transport Proteins - genetics Membrane Transport Proteins - metabolism Oligonucleotide Array Sequence Analysis Pharmacokinetics Pharmacology. Drug treatments Reverse Transcriptase Polymerase Chain Reaction RNA, Messenger - metabolism |
Title | Similarities and Differences in the Expression of Drug-Metabolizing Enzymes between Human Hepatic Cell Lines and Primary Human Hepatocytes |
URI | https://dx.doi.org/10.1124/dmd.110.035873 https://www.ncbi.nlm.nih.gov/pubmed/21149542 https://www.proquest.com/docview/852910465 https://pubmed.ncbi.nlm.nih.gov/PMC3061558 |
Volume | 39 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
journalDatabaseRights | – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 1521-009X dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0014439 issn: 0090-9556 databaseCode: KQ8 dateStart: 19970101 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3JbtswECXc9FKgKLrHXQIeivTQKJUoUsvRTd06bZwusYHcBC1kKyCRjUQGan9C_6__0-Eiic6CLhdBsChR1jyRM6PHNwi9CDye-izIHJ_xwKGEBk5UhMLJPMLjKOdFLmRqYHwYjKb0wzE77vV-WaylRZ3t5qsr15X8j1XhN7CrXCX7D5ZtLwo_wD7YF7ZgYdj-lY2PytMSIlMliqo5xabciaZZKady-MNQXZVf-PZs8c0Z8xpMf1KuZJpgWK2WUrCpIWzprP6Iz5WU655M7R1IarxZVqC1KaxGs3xZGx6i8XFlH7IyterDlOAoypYe1lKAhvuv3k8_tZ70_uBA087SnC-7RmOZTjsatcndN18Hh6PBWHEDda7ITlx4FnPLWisgBzGLnvq50-vW8lNDu87BpFuSZmcy3dh1Yqb1yZtBXSskGfD61gjNzFp0PdkzLS1zeR4hFIxfnBZymcSu67NIF1xZF-y-MJG29EYCTmcU-fQGuknCIJCFNT5-6T5uUerrqMzct9EShT5fr_d4na90e56ewxssdOmVq2KjixRfy2ea3EV3TLCDBxq591CPV_fRtnn6yx1sP-kdvI1tuzxAP214YzATtuCNywoDvHEHbzwT-BK8sYE3NvDGCrnYwBtLeGMFb3V9A2-7kYb3QzR9N5zsjRxTOsTJmU9rhwmYWxgJ8zglLvWE5wdZIMONoohDkceR1DlkoR9GqSQmi0x4IvKCmJNc0NhN_Udoo5pVfBPhyKVBnsYey4S8EsvAZfc4TVMBR9yM95HTGCnJja6-LO9ykqj4mtAEjAo7bqKN2kcv2_Zz_beubek1Nk-MP6z93ARgeu05W2vgaLtoMNlHuEFLAjOJ_DyYVny2OE8iRmLJ-GB99FiDpzvZk4kUSvooXINV20CK1K8fqcrvSqzelzETi5786b6eolvdIPEMbdRnC_4c_P0621Jvz28SMgk1 |
linkProvider | Colorado Alliance of Research Libraries |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Similarities+and+Differences+in+the+Expression+of+Drug-Metabolizing+Enzymes+between+Human+Hepatic+Cell+Lines+and+Primary+Human+Hepatocytes&rft.jtitle=Drug+metabolism+and+disposition&rft.au=LEI+GUO&rft.au=DIAL%2C+Stacey&rft.au=LEMING+SHI&rft.au=BRANHAM%2C+William&rft.date=2011-03-01&rft.pub=American+Society+for+Pharmacology+and+Experimental+Therapeutics&rft.issn=0090-9556&rft.volume=39&rft.issue=3&rft.spage=528&rft.epage=538&rft_id=info:doi/10.1124%2Fdmd.110.035873&rft.externalDBID=n%2Fa&rft.externalDocID=23928834 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0090-9556&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0090-9556&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0090-9556&client=summon |